Compare VENUS REMEDIES with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AJANTA PHARMA VENUS REMEDIES/
AJANTA PHARMA
 
P/E (TTM) x -1.0 22.7 - View Chart
P/BV x 0.1 3.9 1.9% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   AJANTA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
AJANTA PHARMA
Mar-19
VENUS REMEDIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,422 8.9%   
Low Rs61898 6.8%   
Sales per share (Unadj.) Rs301.8233.5 129.2%  
Earnings per share (Unadj.) Rs-24.944.0 -56.6%  
Cash flow per share (Unadj.) Rs2.552.2 4.9%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs293.3255.1 115.0%  
Shares outstanding (eoy) m12.3488.02 14.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.35.0 6.2%   
Avg P/E ratio x-3.826.4 -14.3%  
P/CF ratio (eoy) x36.722.2 165.2%  
Price / Book Value ratio x0.34.5 7.0%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m1,154102,081 1.1%   
No. of employees `0000.96.8 13.6%   
Total wages/salary Rs m3934,307 9.1%   
Avg. sales/employee Rs Th4,026.13,022.6 133.2%   
Avg. wages/employee Rs Th425.0633.4 67.1%   
Avg. net profit/employee Rs Th-331.8569.1 -58.3%   
INCOME DATA
Net Sales Rs m3,72420,554 18.1%  
Other income Rs m23211 10.7%   
Total revenues Rs m3,74720,765 18.0%   
Gross profit Rs m3955,664 7.0%  
Depreciation Rs m338721 46.9%   
Interest Rs m35412 3,054.3%   
Profit before tax Rs m-2755,143 -5.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,273 2.5%   
Profit after tax Rs m-3073,870 -7.9%  
Gross profit margin %10.627.6 38.5%  
Effective tax rate %-11.524.8 -46.4%   
Net profit margin %-8.218.8 -43.8%  
BALANCE SHEET DATA
Current assets Rs m2,63811,812 22.3%   
Current liabilities Rs m2,3053,776 61.0%   
Net working cap to sales %8.939.1 22.9%  
Current ratio x1.13.1 36.6%  
Inventory Days Days13577 175.0%  
Debtors Days Days4682 56.8%  
Net fixed assets Rs m4,87114,398 33.8%   
Share capital Rs m123175 70.4%   
"Free" reserves Rs m3,49622,277 15.7%   
Net worth Rs m3,61922,452 16.1%   
Long term debt Rs m1,3747 20,824.2%   
Total assets Rs m7,50926,962 27.8%  
Interest coverage x0.2444.3 0.1%   
Debt to equity ratio x0.40 129,189.0%  
Sales to assets ratio x0.50.8 65.1%   
Return on assets %0.614.4 4.4%  
Return on equity %-8.517.2 -49.2%  
Return on capital %1.623.0 6.9%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m010,682 0.0%   
Fx outflow Rs m5172,102 24.6%   
Net fx Rs m-5178,580 -6.0%   
CASH FLOW
From Operations Rs m5143,748 13.7%  
From Investments Rs m-123-2,228 5.5%  
From Financial Activity Rs m-387-1,475 26.3%  
Net Cashflow Rs m445 9.3%  

Share Holding

Indian Promoters % 32.9 73.8 44.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 1.6 11.6%  
FIIs % 0.6 7.6 7.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.0 390.6%  
Shareholders   20,121 20,968 96.0%  
Pledged promoter(s) holding % 36.4 4.4 828.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 22, 2019 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS